Seegene’s GMCS data shows 82% pathogen detection in HPV‑positive patients, backing a multiplex diagnostic approach
Executive summary: Seegene shared findings from the Global Million Clinical Study, indicating that 82% of HPV‑positive patients also had detectable reproductive tract pathogens using its STAgora™ platform. The high co‑detection rate suggests that multiplex testing could improve diagnosis and treatment of sexually transmitted infections, potentially affecting clinical pathways.
Who is involved: Seegene, the clinicians and laboratories contributing to the GMCS, and HPV‑positive patient cohorts.
Likely next: Further presentation of the data at medical conferences and pursuit of regulatory clearances for the multiplex assay.
Seegene presented results from its Global Million Clinical Study, where analysis of about 60,000 test results over 42 months revealed that reproductive tract infections were identified in 82% of patients who tested positive for HPV. The company argues that this underscores the clinical value of a comprehensive, panel‑based diagnostic strategy for sexually transmitted infections.
Timeline
- — Seegene предлагает комплексный подход к диагностике инфекций репродуктивного тракта в рамках клинического исследования Global Million Clinical Study (GMCS) (PR Newswire)
Analysis — what this means
Sectors affected
- In vitro diagnostics for sexually transmitted infections